-+ 0.00%
-+ 0.00%
-+ 0.00%

Lunai Bioworks Says Nature Communications Study Identifies Prognostic Biomarkers For Duchenne Muscular Dystrophy Using SomaScan; Lunai Bioworks' BioSymetrics Leads Multi-Institutional Team With Leiden University And University Of Florida

Benzinga·10/16/2025 13:51:18
Listen to the news

Published in Nature Communications, a new study uncovers critical protein biomarkers that predict functional decline in Duchenne Muscular Dystrophy (DMD), opening doors to more personalized care and improved clinical trials.

LEIDEN, THE NETHERLANDS, GAINESVILLE, FL, AND NEW YORK, NY, CA / ACCESS Newswire / October 16, 2025 / In a major advancement for Duchenne muscular dystrophy (DMD) research and patient care, a multi-institutional team led by investigators from Leiden University Medical Center, the University of Florida and BioSymetrics Inc ((a subsidiary of Lunai Bioworks Inc., NASDAQ:LNAI) has identified serum proteins that can serve as prognostic biomarkers in DMD. The study, published today in Nature Communications and supported by Parent Project Muscular Dystrophy (PPMD), analyzed over 700 longitudinal serum samples using the SomaScan® proteomics platform.